Modulating Gliclazide Release and Bioavailability Utilizing Multiparticulate Drug Delivery Systems

Novel Silicone-Grafted Alginate as a Drug Delivery Scaffold: Pharmaceutical Characterization of Gliclazide-Loaded Silicone-Based Composite Microcapsules

“…Gliclazide is a sulfonyl urea (second generation) that has been used for the management of glucose levels in type 2 diabetes patients [ 35 , 36 , 37 , 38 , 39 ]. Gliclazide is a hydrophobic and acidic drug that exhibits pH-dependent solubility (higher solubility in alkaline pH) [ 36 , 40 , 41 ].…”

“…Gliclazide is a sulfonyl urea (second generation) that has been used for the management of glucose levels in type 2 diabetes patients [ 35 , 36 , 37 , 38 , 39 ]. Gliclazide is a hydrophobic and acidic drug that exhibits pH-dependent solubility (higher solubility in alkaline pH) [ 36 , 40 , 41 ]. The Biopharmaceutical Classification System (BCS) recognizes gliclazide as a class II therapeutic agent characterized by high permeability and low solubility, and the significant inter-subject variation is attributed to gliclazide erratic absorption, where the gliclazide maximum plasma concentration is achieved within a rather wide range (2–8 h) following oral administration [ 35 , 36 , 37 ].…”

“…Gliclazide is a hydrophobic and acidic drug that exhibits pH-dependent solubility (higher solubility in alkaline pH) [ 36 , 40 , 41 ]. The Biopharmaceutical Classification System (BCS) recognizes gliclazide as a class II therapeutic agent characterized by high permeability and low solubility, and the significant inter-subject variation is attributed to gliclazide erratic absorption, where the gliclazide maximum plasma concentration is achieved within a rather wide range (2–8 h) following oral administration [ 35 , 36 , 37 ]. Beyond its glycaemic effects, gliclazide also has antioxidant, vascular benefits and neuroprotective effects in diabetic peripheral neuropathy [ 36 , 42 , 43 , 44 , 45 ].…”

“…The Biopharmaceutical Classification System (BCS) recognizes gliclazide as a class II therapeutic agent characterized by high permeability and low solubility, and the significant inter-subject variation is attributed to gliclazide erratic absorption, where the gliclazide maximum plasma concentration is achieved within a rather wide range (2–8 h) following oral administration [ 35 , 36 , 37 ]. Beyond its glycaemic effects, gliclazide also has antioxidant, vascular benefits and neuroprotective effects in diabetic peripheral neuropathy [ 36 , 42 , 43 , 44 , 45 ]. Microparticles (microcapsules) are designed to control or target the drug release of their payload to a certain tissue or organ in a preprogramed fashion [ 46 , 47 ].…”

“…Microparticles (microcapsules) are designed to control or target the drug release of their payload to a certain tissue or organ in a preprogramed fashion [ 46 , 47 ]. The previous literature has outlined various polymers employed in the encapsulation process of many therapeutics including gliclazide [ 36 , 37 , 38 , 39 , 46 , 47 ]. The current study aims to formulate a novel PDMS-grafted alginate platform to encapsulate gliclazide as a drug model by jet nozzle vibration (Buchi B390 encapsulator (Buchi Labortechnik, Flawil, Switzerland)) and to characterize the new platform as well as the produced microcapsules.…”